Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland

Table 1 Summary table on vaccine efficacy assumptions for HPV-related cervical cancer

Vaccine assumptions	HPV 16	HPV 18	HPV 31/33/45/52/58
Vaccine efficacy for preventing cervical HPV16/18/31/33/45/52/58 infections:
Male^a	0.411	0.621	0.411
Female^b	0.76	0.963	0.76
Degree of protection of the vaccine against cervical HPV16/18 infections becoming persistent	0.988	0.984	0.988
Degree of protection of the vaccine against HPV16/18-related CIN	0.979	1	0.979

^aPreventing male genital infections through male vaccination is assumed to prevent transmission of genital infections to females
^bPreventing female genital infections through vaccination is assumed to prevent transmission of genital infections to males
Source: Giuliano et al. (2011) [33] for males and Elbasha and Dasbach [30] for females

ISSN: 1471-2458